BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors, has released an exclusive interview with a spokesman for Biomagnetics Diagnostics Corp. (PINKSHEETS/exchange>: BMGP), the company behind a revolutionary diagnostic systems and technology for malaria, tuberculosis, HIV and hepatitis field testing.
Several key developments have put this company on biotech investors' radar screens in recent weeks and according to one report, the low-float penny stock that is still trading well below analyst estimates.
Diagnostics, the technologies and tools used to identify diseases and conditions in patients, make up the second-largest portion of the biotechnology industry, and this technology allows laboratories to perform far more tests in the same amount of time it takes to do a single test and is designed to detect the actual virus and viral load in any body fluid. Learn more about the company's goals to provide this innovative technology, which was originally developed by the U.S. Department of Homeland Security, via the special report interview which is available now at BioMedReports.Com:
Biotech investors interested in accessing the news portal's complete database of clinical trials and upcoming FDA decisions can access that information here: